Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) Enterprise Value (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Enterprise Value for 17 consecutive years, with -$105.2 million as the latest value for Q1 2026.

  • Quarterly Enterprise Value rose 17.51% to -$105.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$105.2 million through Jan 2026, up 17.51% year-over-year, with the annual reading at -$105.2 million for FY2026, 17.51% up from the prior year.
  • Enterprise Value for Q1 2026 was -$105.2 million at Usana Health Sciences, down from -$91.9 million in the prior quarter.
  • The five-year high for Enterprise Value was -$91.9 million in Q3 2025, with the low at -$364.9 million in Q3 2024.
  • Average Enterprise Value over 5 years is -$238.2 million, with a median of -$246.9 million recorded in 2022.
  • The sharpest move saw Enterprise Value tumbled 30.3% in 2023, then skyrocketed 74.82% in 2025.
  • Over 5 years, Enterprise Value stood at -$288.4 million in 2022, then dropped by 14.56% to -$330.4 million in 2023, then surged by 61.4% to -$127.5 million in 2024, then rose by 27.97% to -$91.9 million in 2025, then decreased by 14.52% to -$105.2 million in 2026.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$105.2 million, -$91.9 million, and -$96.8 million for Q1 2026, Q3 2025, and Q2 2025 respectively.